PBLS (Parabilis Medicines) EV-to-EBITDA: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $30.38
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Parabilis Medicines's enterprise value is $4,254.50 Mil. Parabilis Medicines does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Parabilis Medicines's EV-to-EBITDA at this moment.

The historical rank and industry rank for Parabilis Medicines's EV-to-EBITDA or its related term are showing as below:

PBLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.11   Med: 0   Max: 0
Current: -29.99
PBLS's EV-to-EBITDA is ranked worse than
100% of 402 companies
in the Biotechnology industry
Industry Median: 12.2 vs PBLS: -29.99

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-07-24), Parabilis Medicines's stock price is $30.38. Parabilis Medicines does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Parabilis Medicines's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Parabilis Medicines  (NAS:PBLS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Parabilis Medicines's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=30.38/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Parabilis Medicines EV-to-EBITDA Related Terms

Parabilis Medicines EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines EV-to-EBITDA Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

PBLS vs IDYA, ELVN, BEAM: EV-to-EBITDA Comparison

For the Biotechnology subindustry, Parabilis Medicines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parabilis Medicines EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's EV-to-EBITDA falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines EV-to-EBITDA Calculation

Parabilis Medicines's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4254.499/
=

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.38
Price